Home > Healthcare > Pharmaceuticals > Finished Drug Form > Anti-inflammatory Drugs Market

Anti-inflammatory Drugs Market Trends

Report ID: GMI5976
Published Date: Jun 2023
Report Format: PDF

Download Free Sample

Anti-inflammatory Drugs Market Trends

Increasing prevalence of autoimmune disease and respiratory conditions have significantly created the demand for anti-inflammatory drugs. Autoimmune disease such as rheumatoid arthritis, lupus, and multiple sclerosis are on the rise globally. Various factors such as genetic predisposition, exposure to certain chemicals, hormonal imbalances, smoking, sedentary lifestyle significantly contributes to the autoimmune disease and respiratory conditions.

Therefore, adoption of anti-inflammatory drugs will help suppress the excessive immune response, reduce inflammation and alleviate symptoms. Similarly in respiratory conditions such as asthma and COPD, anti-inflammatory drugs help decrease airway inflammation, bronchoconstriction and mucus production, resulting in improved lung function and symptom control.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Anti-inflammatory drugs industry share was USD 104 billion in 2022 and is estimated to record 8.4% CAGR by 2032, attributed to the high prevalence of inflammatory diseases along with the growing geriatric population worldwide.

The oral segment is expected to grow at 9.2% CAGR by 2032, owing to their rising demand for convenience and ease of accessibility.

North America held over 38.9% of the market revenue share in 2022 driven by the advanced healthcare infrastructure with strong R&D facilities in the region.

Some of the prominent market players include AbbVie Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc among others.